What are TLR9 agonist drugs?

TLR9 agonist drugs are pharmacologic agents that share a common mechanism (typically targeting TLR9). 0 are currently marketed, with 3 more in clinical development.

TLR9 agonist

0 marketed 2 in Phase 3 1 in Phase 2

This page covers all TLR9 agonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting TLR9.

Targets

TLR9

Phase 3 pipeline (2)

SCH 697243 · ALK-Abelló A/S · Oncology
SCH 697243 is a toll-like receptor 9 (TLR9) agonist that activates innate immune responses to enhance anti-tumor immunity.
MGN1703 treatment · Mologen AG · Oncology
MGN1703 is a toll-like receptor 9 (TLR9) agonist that activates innate immune responses to enhance anti-tumor immunity.

Phase 2 pipeline (1)

IMO-2125 · Idera Pharmaceuticals, Inc. · Oncology
IMO-2125 is a synthetic oligonucleotide that acts as a TLR9 agonist, stimulating the innate immune system.